Champions Biotechnology, Inc. Launches PersonalizedCancerTreatment.com
June 01 2009 - 8:52AM
PR Newswire (US)
Website Features Exclusive Personalized Cancer Treatment Options
For Cancer Patients And Healthcare Professionals BALTIMORE, June 1
/PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC:CSBR)
(BULLETIN BOARD: CSBR) , a company engaged in the development of
advanced preclinical platforms and tumor specific data to enhance
the value of oncology drugs, has launched the website
PersonalizedCancerTreatment.com. The website provides information
and access to the company's unparalleled personalized treatment
options for physicians and their patients, including: Personalized
Tumorgraft(TM) A Personalized Tumorgraft is a sample of the
patient's living tumor that is grown and tested in Champions'
facilities. This novel approach optimizes treatment choices through
simultaneous evaluation of the effectiveness of numerous
anti-cancer drugs, sparing the patient from undergoing therapy that
may not be optimal for that specific cancer. Champions also
maintains the patient's living Tumorgraft to allow for future
studies, if needed, for the patient and his/her family.
Personalized Vaccine(TM) A therapeutic cancer vaccine may be
developed from the patient's tumor to provide the most personalized
cancer treatment available. Tumor cells from the Personalized
Tumorgraft are genetically modified, then used to stimulate a
patient's immune system to recognize and, if possible, attack the
patient's cancer cells. Personalized Oncology Panel(TM) Champions'
provides the cancer patient and treating physician with access to
the world's top cancer experts, convening exclusive panels of
renowned experts, selected based on a patient's specific cancer
type and condition, from each of the disciplines critical to the
patient's case. In a round table forum, the expert panel debates
the broad array of options and provides a consensus treatment
recommendation to the patient's physician. The website also
includes a selection of case presentations in the Healthcare
Professional section that demonstrate the positive clinical results
achieved by physicians whose cancer patients have chosen to use
Champions' services. "With the launch of our new website, Champions
empowers Web users to explore, learn, and expand their
understanding of breakthrough cancer treatments, making available
today the personalized oncology options of tomorrow," said Doug
Burkett, Ph.D., President of Champions Biotechnology, Inc. "We are
providing patients and physicians with real-time access to cutting
edge medicine, including valuable insight into the most promising
new cancer treatments, genetic tests, novel therapeutics, landmark
research, and more." Dr. Burkett continued, "Champions offers a
more precise approach to cancer treatment, because every patient's
cancer is unique. In partnership with one's physician, Champions
optimizes a given treatment plan's potential for success and
maximizes the patient's most precious resource: time. We anticipate
the launch of PersonalizedCancerTreatment.com will bring our
exceptional spectrum of personalized cancer treatment options to a
broader audience than ever before." To learn more about
Personalized Cancer Treatment please visit
http://www.personalizedcancertreatment.com/. For more news and
information on Champions Biotechnology, Inc., please visit
http://www.irgnews.com/coi/CSBR where you can find the CEO's video,
a fact sheet on the company, investor presentations, and more.
About Champions Biotechnology, Inc. Champions Biotechnology, Inc.
is engaged in the development of advanced preclinical platforms and
predictive tumor specific data to enhance and accelerate the value
of oncology drugs. The Company was co-founded by David Sidransky,
M.D. who with Manny Hidalgo, M.D., Ph.D. developed the Company's
Preclinical Platform; a novel approach based upon the implantation
of primary human tumors in immune deficient mice followed by
propagation of the resulting engraftments (Biomerk Tumorgrafts(TM))
in a manner that preserves the biological characteristics of the
original human tumor. Early studies suggest that these Tumorgrafts
closely reflect human cancer biology and their response to drugs is
predictive of clinical outcomes in cancer patients. Champions
Biotechnology leverages its preclinical platform to evaluate drug
candidates and to develop a portfolio of novel therapeutic
candidates through pre-clinical trials. As drugs progress through
this early stage of development, the Company plans to sell, partner
or license them to pharmaceutical and/or biotechnology companies,
as appropriate. The Company also offers its predictive preclinical
platform and tumor specific data to physicians for personalized
patient care and to Companies for evaluation of oncology drugs in
models that integrate prognostic testing with biomarker discovery.
Champions Biotechnology is dedicated to enhancing preclinical
development tools, accelerating development and valuation of
oncology drugs, and advancing personalized treatment with a goal to
improve the lives of cancer patients globally. This press release
contains "forward-looking statements" (within the meaning of the
Private Securities Litigation Act of 1995) that inherently involve
risk and uncertainties. Champions Biotechnology generally uses
words such as "believe," "may," "could," "will," "intend,"
"expect," "anticipate," "plan," and similar expressions to identify
forward-looking statements. One should not place undue reliance on
these forward-looking statements. The Company's actual results
could differ materially from those anticipated in the
forward-looking statements for many unforeseen factors. See
Champions Biotechnology's Form 10-KSB for the fiscal year ended
April 30, 2008 for a discussion of such risks, uncertainties and
other factors. Although the Company believes the expectations
reflected in the forward-looking statements are reasonable, they
relate only to events as of the date on which the statements are
made, and Champions Biotechnology's future results, levels of
activity, performance or achievements may not meet these
expectations. The Company does not intend to update any of the
forward-looking statements after the date of this press release to
conform these statements to actual results or to changes in
Champions Biotechnology's expectations, except as required by law.
CHAMPIONS BIOTECHNOLOGY, INC. WEB SITE:
http://www.championsbiotechnology.com/ DATASOURCE: Champions
Biotechnology, Inc. CONTACT: James Carbonara, The Investor
Relations Group, Inc., +1-212-825-3210 or Public Relations: Susan
Morgenbesser or Janet Vasquez, +1-212-825-3210 Web Site:
http://www.championsbiotechnology.com/
Copyright